GB-115 for Health & Longevity

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

GB-115 is an oral protein-fragment medication, prescribed for anxiety in Russia, designed to block a brain messenger linked to fear and panic; elsewhere it circulates as an unregulated powder. Controlled trials, all run by its developer and manufacturer, show reduced anxiety and fatigue in adults with stress-related anxiety over four-week courses. Risks seen so far are mild. Safety beyond four weeks is unknown; any longevity role is untested. (Full Review)

Protocol

Standard regimen
2 mg three times daily
Two 1 mg tablets per dose, for 28 days
Time of day
4–6 hours apart, with or after meals
A morning, midday and early-evening schedule fits this
Dose selection
6 mg/day
3 and 9 mg/day did not reach significance; higher doses offer no documented gain
Time to effect
Reduced anxiety
By two weeks
Separated from placebo in the dose-finding trial; median score fell by day 7 in an after-the-fact pilot analysis
Reduced fatigue
Over 21 days
Median fatigue score fell from 70 to 28 (no control group)
Faster reaction time and attention
From day 7
No control group; practice effects cannot be excluded

Benefits

Contraindications
  • Hypersensitivity to the active substance or tablet ingredients
  • Pregnancy and breastfeeding
  • People under 18 years
  • Hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Active gallbladder disease or gallstones (inferred; no GB-115 data)
Key Interactions
  • Food: about 26% higher exposure with food
Theoretical (inferred from mechanism)
  • Benzodiazepines and other sedative anxiolytics (diazepam, alprazolam): excess drowsiness and impaired driving
  • Opioids (morphine, tramadol): possibly stronger opioid effects, including sedation
  • Antidepressants (sertraline, venlafaxine): unpredictable mood or sleep effects
  • Sedating antihistamines (diphenhydramine) and alcohol: impaired alertness
  • Calming supplements (L-theanine, kava, valerian): excess drowsiness
  • Other CCK receptor blockers (proglumide, dexloxiglumide): greater appetite and gallbladder effects

Risk & Side Effects

  • High:
  • Medium: Mild neurological, mood, sleep and digestive adverse events
  • Low: Increased hunger and calorie intake; reduced gallbladder emptying
  • Speculative: Anxiety from the wrong mirror-image form; strengthened opioid effects; unknown long-term effects

Monitoring

Marker Target Why
HARS total score ≥50% fall from baseline by day 29 Defines response
MFI-20 total score ≤30 points Tracks fatigue
Urine protein (dipstick) Negative Safety check; new proteinuria stops use
ALT and AST (liver enzymes) Within laboratory upper limit, typically ≤40 U/L Safety check; abnormal values place use outside tested conditions
eGFR (kidney filtration) ≥60 mL/min/1.73 m² Safety check; reduced values place use outside tested conditions
Pregnancy test (women of childbearing potential) Negative Safety check; positive result stops use

Cadence: Baseline before starting; anxiety and fatigue scores at 2 weeks and at 4 weeks (day 29); urine protein and liver and kidney tests repeated at 4 weeks; the same panel before restarting and at the end of each further course

Qualitative Assessment

  • Day-to-day worry, tension and irritability
  • Energy and daytime fatigue
  • Sleep onset and quality, and daytime sleepiness
  • Mental clarity and attention at work
  • Appetite, weight and any pain under the right ribs after fatty meals
  • Dizziness or blurred vision